Pharmaceutical Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Daru. 2014 Jun 25;22(1):52. doi: 10.1186/2008-2231-22-52.
Drug-drug interactions (DDIs) are an important type of adverse drug events. Yet overall incidence and pattern of DDIs in Iran has not been well documented and little information is available about the strategies that have been used for their prevention. The purpose of this study was to systematically review the literature on the incidence and pattern of DDIs in Iran as well as the used strategies for their prevention. PubMed, Scopus, electronic Persian databases, and Google Scholar were searched to identify published studies on DDIs in Iran. Additionally, the reference lists of all retrieved articles were reviewed to identify additional relevant articles. Eligible studies were those that analyzed original data on the incidence of DDIs in inpatient or outpatient settings in Iran. Articles about one specific DDI and drug interactions with herbs, diseases, and nutrients were excluded. The quality of included studies was assessed using quality assessment criteria. Database searches yielded 1053 potentially eligible citations. After removing duplicates, screening titles and abstracts, and reading full texts, 34 articles were found to be relevant. The quality assessment of the included studies showed a relatively poor quality. In terms of study setting, 18 and 16 studies have been conducted in inpatient and outpatient settings, respectively. All studies focused on potential DDIs while no study assessed actual DDIs. The median incidence of potential DDIs in outpatient settings was 8.5% per prescription while it was 19.2% in inpatient settings. The most indicated factor influencing DDIs incidence was patient age. The most involved drug classes in DDIs were beta blockers, angiotensin-converting-enzyme inhibitors (ACEIs), diuretic agents, and non-steroidal anti-inflammatory drugs (NSAIDs). Thirty-one studies were observational and three were experimental in which the strategies to reduce DDIs were applied. Although almost all studies concluded that the incidence of potential DDIs in Iran in both inpatient and outpatient settings was relatively high, there is still no evidence of the incidence of actual DDIs. More extensive research is needed to identify and minimize factors associated with incidence of DDIs, and to evaluate the effects of preventive interventions especially those that utilize information technology.
药物-药物相互作用(DDI)是一种重要的药物不良事件类型。然而,伊朗的 DDI 总体发生率和模式尚未得到很好的记录,关于预防 DDI 所使用的策略的信息也很少。本研究的目的是系统地回顾伊朗 DDI 的发生率和模式的文献,以及预防 DDI 所使用的策略。通过 PubMed、Scopus、电子波斯语数据库和 Google Scholar 搜索,以确定在伊朗发表的关于 DDI 的研究。此外,还审查了所有检索到的文章的参考文献,以确定其他相关文章。合格的研究是那些分析了伊朗住院或门诊环境中 DDI 发生率的原始数据的研究。排除了关于特定 DDI 以及草药、疾病和营养素药物相互作用的文章。使用质量评估标准评估纳入研究的质量。数据库搜索产生了 1053 条潜在的合格引文。在去除重复项、筛选标题和摘要以及阅读全文后,发现 34 篇文章相关。纳入研究的质量评估显示出相对较差的质量。就研究设置而言,18 项和 16 项研究分别在住院和门诊环境中进行。所有研究都集中在潜在的 DDI 上,而没有研究评估实际的 DDI。门诊环境中潜在 DDI 的发生率中位数为每处方 8.5%,而住院环境中为 19.2%。影响 DDI 发生率的最主要因素是患者年龄。涉及的药物类别最多的是β受体阻滞剂、血管紧张素转换酶抑制剂(ACEIs)、利尿剂和非甾体抗炎药(NSAIDs)。31 项研究为观察性研究,3 项为实验性研究,其中应用了减少 DDI 的策略。尽管几乎所有研究都得出结论,伊朗住院和门诊环境中潜在 DDI 的发生率都相对较高,但仍没有实际 DDI 发生率的证据。需要进行更广泛的研究,以确定和最小化与 DDI 发生率相关的因素,并评估预防干预措施的效果,特别是利用信息技术的干预措施。